{"database":"ENA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Clevenger Laboratory, Massey Cancer Center, Virginia Commonwealth University"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA320900"],"scientific_name":["Homo sapiens"],"long_description":["The hormone prolactin is implicated in the pathogenesis of breast cancer, and a subset of prolactin-induced gene expression is mediated by HDAC6 activity. The NSAID, bufexamac, is a fairly specific inhibitor of HDAC6 and HDAC10. We used bufexamac in combination with prolactin treatment in MCF7 cells to determine differential expression under these conditions. Overall design: MCF7 cells were serum starved for 24 hours prior to treatment with bufexamac and/or prolactin, and subsequent RNA extraction."],"tag":["xref:PubMed:27358110"],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"Homo sapiens","description":"Gene expression data from MCF7 breast adenocarcinoma cells treated with prolactin and/or bufexamac","dates":{"last_updated":"2025-09-24","first_public":"2016-05-08"},"accession":"PRJNA320900","cross_references":{"GEO":["GSE81217"],"taxon":["9606"],"PubMed":["27358110"]}}